AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06475300
Drug: PD-1 Monoclonal Antibody
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Trial: NCT05860244
Drug: Salbutamol
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol for 6 months
Trial: NCT05632393
Drug: Daridorexant
RxNorm normalized name: Daridorexant
DrugBank: Daridorexant (DB15031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daridorexant will be available as film-coated tablets for oral administration formulated at a strength of 50 mg.
Trial: NCT06130423
Drug: Music intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Music therapy carried out with Music Care
Trial: NCT06130423
Drug: Nicotine replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NRT: Nicotine Patch, Nicotine Gum
Trial: NCT06643091
Drug: Nintedanib
RxNorm normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nintedanib150 mg twice a day for 6 months Or Nintedanib 100mg twice a day in case of dose adjustment Oral route (during meals)
Trial: NCT06641609
Drug: Dose-Escalation (Phase Ia) CFT8919 capsule
RxNorm normalized name: MAGNESIUM ALUMINOMETASILICATE TYPE IA
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Phase 1a，enrolled, eligible patients receive CFT8919 150-900mg twice daily.
Trial: NCT06641609
Drug: Dose-Expansion (Phase Ib) CFT8919 capsule
RxNorm normalized name: monofluorophosphate
DrugBank: Monofluorophosphate ion (DB02348)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 1b，enrolled, eligible patients receive CFT8919 RP2D twice daily.
Trial: NCT06641609
Drug: Cohort-Expansion (Phase Ic) CFT8919 capsule
RxNorm normalized name: monofluorophosphate
DrugBank: Monofluorophosphate ion (DB02348)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 1c，enrolled, eligible patients receive CFT8919 RP2D twice daily.
Trial: NCT06461533
Drug: Susoctocog Alfa (Genetical Recombination)
RxNorm normalized name: susoctocog alfa
DrugBank: Susoctocog alfa (DB11606)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Susoctocog Alfa (Genetical Recombination), Intravenous injection
Trial: NCT06125405
Drug: Telitacicept
RxNorm normalized name: Telitacicept
DrugBank: Telitacicept (DB18312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study duration was 52 weeks, with the experimental group receiving subcutaneous injections of Telitacicept once weekly for a total of 52 weeks.
Trial: NCT06161493
Drug: Niraparib
RxNorm normalized name: Niraparib
DrugBank: Niraparib (DB11793)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: An anti-cancer medication (PARP inhibitor) used for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer .
Trial: NCT05694611
Drug: Sulfur Hexafluoride
RxNorm normalized name: Sulfur hexafluoride
DrugBank: Sulfur hexafluoride (DB11104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To evaluate the differences in brain perfusion and elasticity studied by CEUS and shear-wave elastography, comparing term neonates with and without MRI verified brain pathologies and to compare the ultrasound CEUS and elastography data to MRI.
Trial: NCT05660538
Drug: VX-548
RxNorm normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets for oral administration.
Trial: NCT05660538
Drug: Pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsules for oral administration.
Trial: NCT05759767
Drug: Tamsulosin
RxNorm normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Children in this group will receive medical expulsive therapy in the form of (tamsulosin at a dose of 0.01 mg/kg once daily for 3 weeks after ESWL session.
Trial: NCT04558736
Drug: Anti-Thymocyte Globulin (Rabbit)
RxNorm normalized name: anti-thymocyte globulin (rabbit)
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given intravenously (IV)
Trial: NCT04558736
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given intravenously (IV)
Trial: NCT04558736
Drug: Mesna
RxNorm normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given intravenously (IV)
Trial: NCT04558736
Drug: G-CSF
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Filgrastim is a human granulocyte colony-stimulating factor (G-CSF), produced by recombinant DNA technology. Dosage and Route of Administration: 5mcg/kg subcutaneous or intravenous daily until ANC \>2000 for 2 consecutive days, or as clinically indicated
Trial: NCT06127303
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab treatment (240mg intravenously every 3 weeks) started on day 3 after cryoablation, until occurrence of termination event specified in the protocol.
Trial: NCT05113615
Drug: Tiotropium Bromide
RxNorm normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: respimat inhaler 2.5mcg/puff
Trial: NCT04756531
Drug: PF-07321332 Dose 2
RxNorm normalized name: chloroprocaine
DrugBank: Chloroprocaine (DB01161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PF-07321332 Dose 2 or Placebo
Trial: NCT04756531
Drug: PF-07321332 Dose 3
RxNorm normalized name: hypromellose
DrugBank: Hypromellose (DB11075)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-07321332 Dose 3 or Placebo
Trial: NCT04756531
Drug: PF-07321332 Dose 4
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PF-07321332 Dose 4 or Placebo
Trial: NCT04756531
Drug: PF-07321332 Dose 5
RxNorm normalized name: haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PF-07321332 Dose 5 or Placebo
Trial: NCT04756531
Drug: PF-07321332 Dose 4 or Placebo (Fed)
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: PF-07321332 Dose 5 or Placebo with high fat meal
Trial: NCT06324461
Drug: Dulaglutide 0.75mg subcutaneous injection
DrugBank: Dulaglutide (DB09045)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subject randomized into treatment group will receive single subcutaneous dose of Dulaglutide 0.75mg 7 to 14 days prior to surgery
Trial: NCT04376437
Drug: medical cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhalation by using a Portable Metered-Dose Cannabis Inhaler
Trial: NCT04630769
Drug: IP FT516
RxNorm normalized name: FT516
DrugBank: FT516 (DB15732)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FT516 is an off-the-shelf cryopreserved NK cell product derived from an iPSC that was transduced with a high affinity, ADAM17 non-cleavable CD16 (Fc receptor) that maintains CD16 on the cell surface, which remains fully functional after NK cell activation
Trial: NCT04630769
Drug: Enoblituzumab
RxNorm normalized name: Enoblituzumab
DrugBank: Enoblituzumab (DB15017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoblituzumab is an Fc-optimized monoclonal antibody that targets B7-H3 which is highly expressed on ovarian cancer. Enoblituzumab at 15 mg/kg IV, one day before lymphodepleting chemotherapy
Trial: NCT04630769
Drug: IL-2
RxNorm normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-2 at 6 Million IU (3 Million IU/m2 if patient weight is \<45 kg) is administered IP in 50 cc of room temperature D5W via peritoneal catheter directly after the FT-516 infusion is completed. Immediately following the IL-2, an additional 100 cc D5W flush is infused into the peritoneal cavity through the peritoneal catheter as rapidly as possible.
Trial: NCT06248710
Drug: Oxytocin nasal spray
RxNorm normalized name: oxytocin Nasal Spray
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Syntocinon nose spray is usually applied in the context of labour and breast feeding. In this study, however, it will be used to induce an oxytocin (OT) release. Participants will apply three sprays in each nostril which will result in a dose of 24 I.U of oxytocin per participant
Trial: NCT04661358
Drug: Fenofibrate
RxNorm normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants begin with a dose of either 160mg or 54mg fenofibrate, based on eGFR value at screening, taken once daily with food. The dose may be adjusted during follow-up based on protocol guidelines.
Trial: NCT03686657
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1000 mg metformin-HCL XR once-a-day or maintenance dose of metformin for 26 weeks
Trial: NCT05641766
Drug: THC
RxNorm normalized name: THC
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive THC into a rapidly flowing IV infusion.
Trial: NCT06479239
Drug: EGFR FPBMC
RxNorm normalized name: Egfr t790m inhibitor pf-06747775
DrugBank: Mavelertinib (DB16228)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 8 weekly infusions of EGFR FPBMC, then 8 additional infusions every 2 weeks.
Trial: NCT05024344
Drug: Ropivacaine 0.5% Injectable Solution
RxNorm normalized name: ROPivacaine 0.5% injectable solution
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The Anesthesiologist will use ultrasound-guided technique and inject 30mL of 0.5% ropivacaine with 4 mg of dexamethasone or saline placebo control into the erector spinae muscle, superficial to the tips of the thoracic transverse processes
Trial: NCT05024344
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The Anesthesiologist will use ultrasound-guided technique and inject 30mL of 0.5% ropivacaine with 4 mg of dexamethasone or saline placebo control into the erector spinae muscle, superficial to the tips of the thoracic transverse processes
Trial: NCT06247748
Drug: Exendin-4 Fc fusion protein (JY09) injection
RxNorm normalized name: Exendin 4
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D22 received a single subcutaneous abdominal injection of 1.2 mg of JY09 injection after completion of PK blood sampling; D29, D36, D43, D50, D57, D64, D71, and D78 subjects returned to the study center to receive a subcutaneous abdominal injection of 2.4 mg of JY09 injection(total of 8 administrations).All doses were to be administered within 3 min.
Trial: NCT06247748
Drug: Metformin Hydrochloride tablet
RxNorm normalized name: Metformin Hydrochloride Tablets
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: D1 to D4 continuous oral administration of 0.5 g metformin hydrochloride tablets twice daily (D4 was administered only in the morning, with a total of 7 administrations) for a washout period of 96 h;0.5 g metformin hydrochloride tablets orally twice a day continuously from D85 to D88 (D88 was given only in the morning, for a total of 7 doses).
Trial: NCT06247748
Drug: Digoxin tablet
RxNorm normalized name: Digoxin Tablets
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D15 received a single oral administration of 0.25 mg digoxin tablets in the morning, with a washout period of 168 h,oral 0.25 mg digoxin tablets 72 h±0.5 h after JY09 administration (D102)
Trial: NCT04992273
Drug: casirivimab+imdevimab
RxNorm normalized name: casirivimab / imdevimab
DrugBank: Imdevimab (DB15940)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single dose administered based on weight
Trial: NCT05994287
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients received aspirin in a dose of 100 mg orally daily.
Trial: NCT04120987
Drug: Lifitegrast 5% Ophthalmic Solution
RxNorm normalized name: Lifitegrast 5% Ophthalmic Solution
DrugBank: Lifitegrast (DB11611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BID OU
Trial: NCT06456892
Drug: Pucotenlimab
RxNorm normalized name: Pucotenlimab
DrugBank: Pucotenlimab (DB17552)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pucotenlimab Combined with Standard Chemotherapy Regimen
Trial: NCT05880524
Drug: Dornase Alfa
RxNorm normalized name: Dornase Alfa
DrugBank: Dornase alfa (DB00003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive an intravenous dose of Dornase alfa twice within within 24±6 hours after symptom onset, administered as a bolus.
Trial: NCT04908228
Drug: Ibrutinib and obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Rutin (DB01698)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive fixed-duration treatment with ibrutinib and obinutuzumab.
Trial: NCT05862792
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: We will inject liposomal bupivacaine into the surgical bed.
Trial: NCT05903703
Drug: Canagliflozin and Gemcitabine
RxNorm normalized name: metformin and canagliflozin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: on the first, 8th and 15th day of treatment, patients were given intravenous drip of 1000mg/m2 gemcitabine, and 21 days was a course of treatment, lasting for 6 courses.~Take 400mg canagliflozin orally every day, and continue to use it until the end of chemotherapy. According to the patient's tolerance to disulfiram, the dose of canagliflozin can be re-evaluated during the treatment, and the highest dose is 125mg per day. The clinical symptoms, signs and adverse reactions of patients were observed, and the treatment effect of patients was evaluated after two consecutive cycles with 4 weeks as a cycle
Trial: NCT05903703
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: on the first, 8th and 15th day of treatment, patients were given 1000mg/m2 gemcitabine intravenously, and 21 days was a course of treatment, lasting for 6 courses.
Trial: NCT00000720
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04940078
Drug: Cagrilintide
RxNorm normalized name: Cagrilintide
DrugBank: Cagrilintide (DB18887)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once weekly doses of cagrilintide gradually increased to 1.7 mg over 14 weeks and 2.4 mg s.c. for 2 weeks
Trial: NCT04940078
Drug: semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Once weekly doses of semaglutide gradually increased to 1.7 mg over 14 weeks and 2.4 mg s.c. over 2 weeks
Trial: NCT04940078
Drug: Cagrilintide and semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cagrilintide and semaglutide combined and administered using the DV3384 manual syringe
Trial: NCT06465238
Drug: SHR-A2009
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group: Subjects will receive an intravenous infusion of SHR-A2009 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
Trial: NCT06465238
Drug: SHR-A1921
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group: Subjects will receive an intravenous infusion of SHR-A1921 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
Trial: NCT05077969
Drug: Famotidine
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80 mg tablet, QID for 14 days
Trial: NCT05473715
Drug: Aflibercept(BAY86-5321, Eylea)
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2mg, intravitreal (IVT) injection
Trial: NCT06638008
Drug: perineural injection
RxNorm normalized name: ROPIVACAINE HYDROCHLORIDE 2 mg in 1 mL PERINEURAL INJECTION
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: perineural intervention of placental growth factor in one group and PRP in other group
Trial: NCT05731245
Drug: Ropeginterferon Alfa-2B Prefilled Syringe [Besremi]
RxNorm normalized name: ropeginterferon alfa-2b Prefilled Syringe [Besremi]
DrugBank: Peginterferon alfa-2b (DB00022)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eligible subjects will receive Ropeginterferon alfa-2b subcutaneously (SC) every 2 weeks at the starting dose of 250µg at week 0, 350 µg at week 2, then 500µg at a fixed dose from week 4 onwards
Trial: NCT06417060
Drug: Caudal block anesthesia
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthesia will be administered via inhalation induction with air/nitrous oxide and sevoflurane, followed by an injection of 0.25% bupivacaine (1 mL/kg) without epinephrine into the caudal canal, which is the sacral portion of the spinal canal.
Trial: NCT06417060
Drug: Dorsal penile block anesthesia
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthesia will be administered using an inhalation induction method with air/nitrous oxide and sevoflurane, followed by the injection of 0.25% bupivacaine without epinephrine into the dorsal part of the penis.
Trial: NCT05532800
Drug: JS002
RxNorm normalized name: Immunoglobulin g4, anti-(neural apoptosis-regulated convertase 1) (human monoclonal js002 .gamma.4-chain), disulfide with human monoclonal js002 .kappa.-chain, dimer
DrugBank: Ongericimab (DB18949)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JS002:150mg(1mL) Q2W PFS, Placebo: 1mL Q2W PFS.
Trial: NCT05093608
Drug: Selinexor Pill
RxNorm normalized name: selinexor Pill
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Selinexor 60 mg or 80 mg (oral table) will be administered once a week.
Trial: NCT05093608
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab will be administered at a standard dose of 15 mg/kg every 3 weeks.
Trial: NCT05093608
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab will be administered intravenously a standard dose of 12,000 mg every 3 weeks.
Trial: NCT05492045
Drug: D-1553
RxNorm normalized name: D
DrugBank: Rosomidnar (DB17154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-1553 is a novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation.
Trial: NCT06270056
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered misoprostol by clients obtaining medication abortion via telemedicine
Trial: NCT04891198
Drug: Envafolimab
RxNorm normalized name: Envafolimab
DrugBank: Envafolimab (DB15769)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection
Trial: NCT05164653
Drug: Sacubitril Valsartan Sodium Hydrate
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Switch from the ACE inhibitor or ARB that was taken before the allocation, and start oral administration twice daily with a starting dose of 50 mg of sacubitril valsartan. The duration of administration of the ACE inhibitor or ARB before allocation does not matter, but when switching from the ACE inhibitor, administration of sacubitril valsartan should be started at least 36 hours after the final administration of the drug.~After the start of administration, the dose is gradually increased to 100 mg and 200 mg once at intervals of 2 to 4 weeks, referring to the latest package insert and safety and tolerability standards. At that time, if the doctor in charge determines that the dose is not tolerated after the dose is increased, the dose may be reduced to the previous dose or the drug may be suspended depending on the medical situation.
Trial: NCT06637150
Drug: Dalpicilib
RxNorm normalized name: Dalpiciclib
DrugBank: Dalpiciclib (DB17456)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalpicilib 100 mg once daily from day 1 to day 21, every 4 weeks, for a total of 3 years, in combination with endocrine therapy for 5 years.
Trial: NCT04892277
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04892277
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04938427
Drug: Soticlestat
RxNorm normalized name: Soticlestat
DrugBank: Soticlestat (DB16987)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soticlestat mini-tablets or tablets.
Trial: NCT06129955
Drug: Pucotenlimab Combined With Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients treated by Pucotenlimab combined with Lenvatinib for 3 months before surgery
Trial: NCT06583343
Drug: OnabotulinumtoxinA
RxNorm normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Botulinum toxin injections were administered in appropriate doses to the spastic muscles of children with cerebral palsy.
Trial: NCT05946551
Drug: Cetirizine
RxNorm normalized name: Cetirizine
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cetirizine will be dispensed as a 10mg capsule with instructions for patients to take one capsule daily by mouth, preferably at bedtime.
Trial: NCT05946551
Drug: Famotidine
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Famotidine will be dispensed in 20mg capsules with instructions for patients to take one capsule twice daily, as close to the same times every day as possible.